Cellebrite DI (CLBT) Liabilities and Shareholders Equity (2020 - 2026)

Cellebrite DI has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $994.3 million in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 26.27% year-over-year to $994.3 million in Q2 2026; TTM through Jun 2026 was $3.7 billion, a 32.04% increase from a year earlier, with the FY2025 full-year figure at $938.9 million, up 35.95% from the prior year.
• Liabilities and Shareholders Equity was $994.3 million for Q2 2026 at Cellebrite DI, up from $952.3 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $994.3 million in Q2 2026, with the low at $221000.0 in Q2 2022.
• Average Liabilities and Shareholders Equity over 5 years is $586.2 million, with a median of $544.7 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity grew 11.85% in 2022, then jumped 192611.76% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $403.3 million in 2022, then jumped by 32.13% to $532.9 million in 2023, then grew by 29.59% to $690.6 million in 2024, then surged by 35.95% to $938.9 million in 2025, then advanced by 5.91% to $994.3 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $994.3 million (Q2 2026), $952.3 million (Q1 2026), and $938.9 million (Q4 2025), per Business Quant data.